Cited by 940SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Open access

Lumley, Sheila F., O’Donnell, Denise, Stoesser, Nicole E., Matthews, Philippa C., Howarth, Alison, Hatch, Stephanie B., Marsden, Brian D., Cox, Stuart, James, Tim, Warren, Fiona, Peck, Liam J., Ritter, Thomas G., de Toledo, Zoe, Warren, Laura, Axten, David, Cornall, Richard J., Jones, E. Yvonne, Stuart, David I., Screaton, Gavin, Ebner, Daniel, Hoosdally, Sarah, Chand, Meera, Crook, Derrick W., O’Donnell, Anne-Marie, Conlon, Christopher P., Pouwels, Koen B., Walker, A. Sarah, Peto, Tim E.A., Hopkins, Susan, Walker, Timothy M., Jeffery, Katie, Eyre, David W.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2034545PMC PMC7781098

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. METHODS: We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time. RESULTS: A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P = 0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status. CONCLUSIONS: The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2034545

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Vaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Genomic evidence for reinfection with SARS-CoV-2: a case study
Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N. F., Gorzalski, A. J., Laverdure, C., Verma, S. C., Rossetto, C. C., Jackson, D. K., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30764-7 · Cited by 755
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 2

Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J Infect Dis 2020 November 3 (Epub ahead of print).33140086
To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020 August 25 (Epub ahead of print).32840608

Sorted by citations

Items 101–200 of 913

Correlates of protection from SARS-CoV-2 infection
Krammer, F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00782-0 · Cited by 89
Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019: Serologic Testing
Hayden, M. K., Mikati, I. K. E., Hanson, K. E., Englund, J. A., Humphries, R. M., Lee, F., Loeb, M. B., Morgan, D. J., Patel, R., Ta’ani, O. A., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae121 · Cited by 89
Risk of reinfection and disease after SARS‐CoV ‐2 primary infection: Meta‐analysis
Flacco, M. E., Martellucci, C. A., Baccolini, V., Vito, C. D., Renzi, E., Villari, P., & Manzoli, L. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13845 · Cited by 90
Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
Perry, J. A., Osman, S., Wright, J., Richard‐Greenblatt, M., Buchan, S. A., Sadarangani, M., & Bolotin, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266852 · Cited by 93
Quantifying the risk of SARS‐CoV‐2 reinfection over time
O Murchu, E., Byrne, P., Carty, P. G., De Gascun, C., Keogan, M., O’Neill, M., Harrington, P., & Ryan, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2260 · Cited by 84
Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
Xiang, T., Liang, B., Fang, Y., Lu, S., Li, S., Wang, H., Li, H., Yang, X., Shěn, S., Zhu, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708523 · Cited by 84
Three SARS-CoV-2 reinfection cases by the new Variant of Concern (VOC) P.1/501Y.V3Preprint
Naveca, F. G., da Costa, C. F., do Nascimento, V. A., de Souza, V. C., Corado, A. D. L. G., Nascimento, F., Costa, Á., Duarte, D., Silva, G., Mejía, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-318392/v1 · Cited by 83
Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine
Nomura, Y., Sawahata, M., Nakamura, Y., Kurihara, M., Koike, R., Katsube, O., Hagiwara, K., Niho, S., Masuda, N., Tanaka, T., et al. (2021) · Vaccines · doi:10.3390/vaccines9091042 · Cited by 83
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis
Chisale, M., Ramazanu, S., Mwale, S. E., Kumwenda, P., Chipeta, M. C., Kaminga, A. C., Nkhata, O., Nyambalo, B. W., Chavura, E., & Mbakaya, B. C. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2271 · Cited by 81
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
Charmet, T., Schaeffer, L., Grant, R., Galmiche, S., Chény, O., Von Platen, C., Maurizot, A., Rogoff, A., Omar, F., David, C., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100171 · Cited by 80
Immunity to SARS-CoV-2 up to 15 months after infection
Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., Kumagai‐Braesch, M., Andréll, J., Percivalle, E., Sammartino, J. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103743 · Cited by 83
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review
Jones, J., Faruqi, A. J., Sullivan, J., Calabrese, C. M., & Calabrese, L. H. (2021) · Pathogens and Immunity · doi:10.20411/pai.v6i1.435 · Cited by 79
Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
Charmetant, X., Espi, M., Benotmane, I., Barateau, V., Heibel, F., Buron, F., Gautier-Vargas, G., Delafosse, M., Perrin, P., Koenig, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6141 · Cited by 84
Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
Hurlburt, N. K., Homad, L. J., Sinha, I. R., Jennewein, M. F., MacCamy, A. J., Wan, Y.-H., Boonyaratanakornkit, J. B., Sholukh, A. M., Jackson, A. M., Zhou, P.-P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03262-7 · Cited by 80
COVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals
Shields, A. M., Faustini, S. E., Kristunas, C., Cook, A. M., Backhouse, C., Dunbar, L., Ebanks, D., Emmanuel, B., Crouch, E., Kröger, A., et al. (2021) · Journal of Dental Research · doi:10.1177/00220345211020270 · Cited by 80
The role of B cells in COVID-19 infection and vaccination
Chen, S., Guan, F., Candotti, F., Benlagha, K., Câmara, N. O. S., Herrada, A. A., James, L. K., Lei, J., Miller, H., Kubo, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988536 · Cited by 75
Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong
Chen, L.-L., Abdullah, S. M. U., Chan, W.-M., Chan, B. P.-C., Ip, J. D., Chu, A. W.-H., Lu, L., Zhang, X., Zhao, Y., Chuang, V. W.-M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31395-0 · Cited by 72
Patient Characteristics and Costs Associated With COVID-19–Related Medical Care Among Medicare Fee-for-Service Beneficiaries
Tsai, Y., Vogt, T. M., & Zhou, F. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1102 · Cited by 72
Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?
Romagnoli, R., Gruttadauria, S., Tisone, G., Ettorre, G. M., Carlis, L. G. D., Martini, S., Tandoi, F., Trapani, S., Saracco, M., Luca, A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16823 · Cited by 72
Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study
Mo, Y., Eyre, D. W., Lumley, S., Walker, T. M., Shaw, R. H., O’Donnell, D., Butcher, L., Jeffery, K. J., Donnelly, C. A., Oxford COVID infection review team, et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003816 · Cited by 72
Self-citation
SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India
Malhotra, S., Mani, K., Lodha, R., Bakhshi, S., Mathur, V. P., Gupta, P., Kedia, S., Sankar, J., Kumar, P., Kumar, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42210 · Cited by 73
Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
Chen, L., Chua, G. T., Lu, L., Chan, B. P.-C., Wong, J. S. C., Chow, C. C. K., Yu, T.-C., Leung, A. S. Y., Lam, S.-Y., Wong, T.-W., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2035195 · Cited by 71
Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing
Qureshi, A. I., Baskett, W. I., Huang, W., Lobanova, I., Naqvi, S. H., & Shyu, C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab345 · Cited by 70
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
Lau, E. H. Y., Hui, D. S. C., Tsang, O. T., Chan, W. H., Kwan, M. Y. W., Chiu, S. S. S., Cheng, S. M. S., Ko, R. L., Li, J. K., Chaothai, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101174 · Cited by 71
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
Lumley, S., Rodger, G., Constantinides, B., Sanderson, N. D., Chau, K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab608 · Cited by 73
Self-citation
Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review
Boroumand, A. B., Forouhi, M., Karimi, F., Moghadam, A. S., Naeini, L. G., Kokabian, P., & Naderi, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940357 · Cited by 71
Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 70
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Clarke, C., Prendecki, M. F., Dhutia, A., Gan, J. J. L., Edwards, C., Prout, V., Lightstone, L., Parker, E. L., Marchesin, F., Griffith, M. E., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.009 · Cited by 68
Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection
Lin, Y., Wang, G., Shen, Y., Wang, Z.-Y., Zhan, B.-D., Duan, L., Lu, B., Shi, C., Gao, Y., Peng, H.-H., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab255 · Cited by 69
Scenario analysis of COVID-19 transmission dynamics in Malaysia with the possibility of reinfection and limited medical resources scenarios
Salman, A. M., Ahmed, I., Mohd, M. H., Jamiluddin, M. S., & Dheyab, M. A. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104372 · Cited by 64
Similarity of Protection Conferred by Previous SARS-CoV-2 Infection and by BNT162b2 Vaccine: A 3-Month Nationwide Experience From Israel
Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., Freedman, L. S., & Huppert, A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac060 · Cited by 64
Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study
Krutikov, M., Palmer, T., Tut, G., Fuller, C., Shrotri, M., Williams, H., Davies, D., Irwin-Singer, A., Robson, J., Hayward, A. C., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00093-3 · Cited by 64
Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study
Leidi, A., Koegler, F., Dumont, R., Dubos, R., Zaballa, M.-E., Piumatti, G., Coen, M., Berner, A., Farhoumand, P. D., Vetter, P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab495 · Cited by 62
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 63
Multiple COVID-19 Waves and Vaccination Effectiveness in the United States
Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 62
Effects of COVID-19 pandemic on mental health among frontline healthcare workers: A systematic review and meta-analysis
Tong, J., Zhang, J., Zhu, N., Pei, Y., Liu, W., Yu, W., Hu, C., & Sun, X. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1096857 · Cited by 67
Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study
Hozé, N., Paireau, J., Lapidus, N., Kiem, C. T., Salje, H., Severi, G., Touvier, M., Zins, M., de Lamballerie, X. N., Lévy-Bruhl, D., et al. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00064-5 · Cited by 60
Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
Slezak, J. M., Bruxvoort, K. J., Fischer, H. J., Broder, B. I., Ackerson, B. K., & Tartof, S. Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.030 · Cited by 60
Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis
Mao, Y., Wang, W., Ma, J., Wu, S., & Sun, F. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001892 · Cited by 60
SARS-CoV-2: Targeted managements and vaccine development
Bakhiet, M., & Taurin, S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.11.001 · Cited by 65
Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals
Fraley, E., LeMaster, C., Geanes, E. S., Banerjee, D., Khanal, S., Grundberg, E., Selvarangan, R., & Bradley, T. (2021) · BMC Medicine · doi:10.1186/s12916-021-02055-9 · Cited by 61
The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery
Peghin, M., Martino, M. D., Fabris, M., Palese, A., Visintini, E., Graziano, E., Gerussi, V., Bontempo, G., D’Aurizio, F., Biasotto, A., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01138-21 · Cited by 61
Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review
Soetedjo, N. N. M., Iryaningrum, M. R., Lawrensia, S., & Permana, H. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102406 · Cited by 59
Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19
Dobaño, C., Ramírez‐Morros, A., Alonso, S., Vidal‐Alaball, J., Ruiz‐Olalla, G., Vidal, M., Rubio, R., Cascant, E., Parras, D., Melero, N. R., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02032-2 · Cited by 58
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study
Shields, A. M., Faustini, S. E., Hill, H. J., Al‐Taei, S., Tanner, C., Ashford, F. B., Workman, S., Moreira, F., Verma, N., Wagg, H., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01231-7 · Cited by 58
Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 60
Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan
Yazaki, S., Yoshida, T., Kojima, Y., Yagishita, S., Nakahama, H., Okinaka, K., Matsushita, H., Shiotsuka, M., Kobayashi, O., Iwata, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2159 · Cited by 57
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England
Jeffery-Smith, A., Rowland, T. A. J., Patel, M., Whitaker, H., Iyanger, N., Williams, S. V., Giddings, R., Thompson, L., Zavala, M., Aiano, F., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00253-1 · Cited by 60
Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study
Kim, P., Gordon, S. M., Sheehan, M. M., & Rothberg, M. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab999 · Cited by 58
Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination
Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S. A., Intinis, C. D., Fesi, F., Gizzi, K., Macagno, M., Montone, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01313-z · Cited by 58
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
Siggins, M. K., Thwaites, R. S., & Openshaw, P. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.016 · Cited by 61
Insights into SARS-CoV-2 Persistence and Its Relevance
Desimmie, B. A., Raru, Y., Awadh, H., He, P., Teka, S., & Willenburg, K. S. (2021) · Viruses · doi:10.3390/v13061025 · Cited by 58
Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00198-0 · Cited by 57
Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020
Jeffery-Smith, A., Iyanger, N., Williams, S. V., Chow, J. Y., Aiano, F., Höschler, K., Lackenby, A., Ellis, J., Platt, S., Miah, S., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.5.2100092 · Cited by 53
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
Xu, Q., Xue, J.-H., Xiao, Y., Jia, Z.-J., Wu, M., Liu, Y., Li, W.-L., Liang, X., & Yang, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786554 · Cited by 53
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
Whitcombe, A. L., McGregor, R., Craigie, A., James, A., Charlewood, R., Lorenz, N., Dickson, J. M. J. J., Sheen, C. R., Koch, B., Fox‐Lewis, S., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1261 · Cited by 52
Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results
Lombardi, A., Bozzi, G., Ungaro, R., Villa, S., Castelli, V., Mangioni, D., Muscatello, A., Gori, A., & Bandera, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657711 · Cited by 51
Observed Protection Against SARS-CoV-2 Reinfection Following a Primary Infection: A Danish Cohort Study Using Two Years of Nationwide PCR-Test Data
Michlmayr, D., Hansen, C. H., Gubbels, S., Valentiner‐Branth, P., Bager, P., Obel, N., Drewes, B., Møller, C. H., Møller, F. T., Legarth, R. A., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100452 · Cited by 51
Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months
Breathnach, A. S., Riley, P. A., Cotter, M., Houston, A., Habibi, M. S., & Planche, T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.005 · Cited by 51
Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers
Martínez‐Gallo, M., Esperalba, J., Pujol‐Borrell, R., Sandá, V., Arrese-Muñoz, I., Fernández‐Naval, C., Antón, A., Cardona, V., Labrador‐Horrillo, M., Pumarola, T., et al. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.09.013 · Cited by 50
Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis
Deng, L., Li, P., Zhang, X., Jiang, Q., Turner, D. E., Zhou, C., Gao, Y., Qian, F., Zhang, C., Lu, H. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24220-7 · Cited by 50
Adult multisystem inflammatory syndrome in a patient who recovered from COVID-19 postvaccination
Uwaydah, A. K., Hassan, N. M. M., Ghoush, M. S. A., & Shahin, K. M. M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242060 · Cited by 49
Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys
Alkharaan, H., Bayati, S., Hellström, C., Aleman, S., Olsson, A., Lindahl, K., Bogdanović, G., Healy, K., Tsilingaridis, G., Palma, P., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab256 · Cited by 51
The association between obesity and peak antibody titer response in COVID‐19 infection
Soffer, S., Glicksberg, B. S., Zimlichman, E., Efros, O., Levin, M. A., Freeman, R., Reich, D. L., & Klang, E. (2021) · Obesity · doi:10.1002/oby.23208 · Cited by 48
COVID-19 Infection in Children: Diagnosis and Management
Zhu, F. H., & Ang, J. Y. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00779-0 · Cited by 53
An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination statusPreprint
Lumley, S., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21253218 · Cited by 48
Self-citation
Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection
Helfand, M., Fiordalisi, C. V., Wiedrick, J., Ramsey, K. L., Armstrong, C., Gean, E., Winchell, K., & Arkhipova-Jenkins, I. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4245 · Cited by 47
Nowcasting epidemics of novel pathogens: lessons from COVID-19
Wu, J. T. K., Leung, K. S. M., Lam, T. T., Ni, M. Y., Wong, C. K. H., Peiris, M. J. S., & Leung, G. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01278-w · Cited by 48
Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020
Ayoub, H. H., Mumtaz, G. R., Seedat, S., Makhoul, M., Chemaitelly, H. S., & Abu-Raddad, L. J. (2021) · Global Epidemiology · doi:10.1016/j.gloepi.2021.100068 · Cited by 48
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
Schultz, B. M., Melo-González, F., Duarte, L. F., Gálvez, N. M. S., Pacheco, G. A., Soto, J. A., Berríos-Rojas, R. V., González, L. A., Moreno‐Tapia, D., Rivera-Pérez, D., et al. (2022) · mBio · doi:10.1128/mbio.01423-22 · Cited by 47
Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections
Ahmad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742167 · Cited by 46
Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
Dinç, H. Ö., Saltoğlu, N., Can, G., Balkan, İ. İ., Budak, B., Özbey, D., Çağlar, B., Karaali, R., Mete, B., Tok, Y., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.051 · Cited by 46
Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
de Gier, B., Huiberts, A. J., Hoeve, C. E., den Hartog, G., van Werkhoven, C. H., van Binnendijk, R. S., Hahné, S. J. M., de Melker, H. E., van den Hof, S., & Knol, M. J. (2023) · Nature Communications · doi:10.1038/s41467-023-40195-z · Cited by 46
COVID-19, the first pandemic in the post-genomic era
van Dorp, L., Houldcroft, C. J., Richard, D., & Balloux, F. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.07.002 · Cited by 49
Immunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 46
Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here
Halperin, D. T., Hearst, N., Hodgins, S., Bailey, R. C., Klausner, J. D., Jackson, H., Wamai, R. G., Ladapo, J. A., Over, M., Baral, S., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12082-z · Cited by 47
Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection
Wagner, K. I., Mateyka, L. M., Jarosch, S., Grass, V., Weber, S., Schober, K., Hammel, M., Burrell, T., Kalali, B. N., Poppert, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110214 · Cited by 47
Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · doi:10.1101/2021.04.20.440647 · Cited by 43
Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection
Burack, D., Pereira, M. R., Tsapepas, D. S., Harren, P. A., FARR, M. A., Arcasoy, S. M., Cohen, D. J., Mohan, S., Emond, J. C., Hod, E. A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16541 · Cited by 45
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
Sandberg, J. T., Varnaitė, R., Christ, W., Chen, P., Muvva, J. R., Maleki, K. T., García, M., Dzidic, M., Folkesson, E., Skagerberg, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1306 · Cited by 45
Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
Montesinos, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104988 · Cited by 44
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
Arora, P., Zhang, L., Krüger, N., Rocha, C., Sidarovich, A., Schulz, S. R., Kempf, A. M., Graichen, L., Moldenhauer, A.-S., Cossmann, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.04.017 · Cited by 45
Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants
Yang, Z. L., Zhang, S., Tang, Y., Zhang, S., Xu, D.-Q., Yue, S., & Liu, Q. (2022) · Aging and Disease · doi:10.14336/ad.2021.1210 · Cited by 46
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Diani, S., Leonardi, E. A., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., Bouslenko, Z., Natalini, D., Conti, S., Mantovani, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216272 · Cited by 44
Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials
Rapaka, R. R., Hammershaimb, E. A., & Neuzil, K. M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab213 · Cited by 44
Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
Meyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 44
Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities
Gudina, E. K., Ali, S., Abera, E. G., Gize, A., Tegene, B., Hundie, G. B., Sime, W. T., Ambachew, R., Gebreyohanns, A., Bekele, M., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00386-7 · Cited by 45
Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review
Alsobaie, S. F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s306441 · Cited by 42
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
Etyang, A. O., Lucinde, R. K., Karanja, H., Kalu, C., Mugo, D., Nyagwange, J., Gitonga, J. N., Tuju, J., Wanjiku, P., Karani, A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab346 · Cited by 42
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2
McConnell, D. J., Hickey, C., Bargary, N., Trela-Larsen, L., Walsh, C., Barry, M. G., & Adams, R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094640 · Cited by 43
Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers
Bonnet, B., Chabrolles, H., Archimbaud, C., Brebion, A., Cosme, J., Dutheil, F., Lambert, C., Junda, M., Mirand, A., Ollier, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842912 · Cited by 43
Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods
Anastassopoulou, C. G., Antoni, D., Manoussopoulos, Y. N., Stefanou, P., Argyropoulou, S., Vrioni, G., & Tsakris, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266958 · Cited by 42
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
García-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., Al-Delfi, Z., Abayasingam, A., Agapiou, D., Stella, A. O., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100651 · Cited by 43
Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study
Masiá, M., Fernández‐González, M., Telenti, G., Agulló, V., García, J. A., Padilla, S., García‐Abellán, J., Galiana, A., Gonzalo-Jiménez, N., & Gutiérrez, F. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102703 · Cited by 41
COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis
Flacco, M. E., Martellucci, C. A., Baccolini, V., Vito, C. D., Renzi, E., Villari, P., & Manzoli, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1023507 · Cited by 41
Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations
Cohen, L., Spiro, D. J., & Viboud, C. G. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010591 · Cited by 42
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Benkeser, D. C., Fong, Y., Janes, H., Kelly, E. J., Hirsch, I., Sproule, S., Stanley, A. M., Maaske, J., Villafana, T. L., Houchens, C. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00630-0 · Cited by 41
Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response
Ontañón, J., Blas, J., de Cabo, C., Santos, C. P., Taravilla, E. R.-E., García, A., Marı́n, L., Sáez, L., Beato, J. L., Rada, R., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103656 · Cited by 41

Authors: Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., Peck, L. J., Ritter, T. G., de Toledo, Z., Warren, L., Axten, D., Cornall, R. J., Jones, E. Y., Stuart, D. I., Screaton, G., Ebner, D., Hoosdally, S., Chand, M., Crook, D. W., O’Donnell, A.-M., Conlon, C. P., Pouwels, K. B., Walker, A. S., Peto, T. E. A., Hopkins, S., Walker, T. M., Jeffery, K., & Eyre, D. W.
Affiliations: Public Health England (GB)
From Oxford University Hospitals NHS Foundation Trust (S.F.L., N.E.S., P.C.M., S.C., T.J., F.W., L.W., D.A., A.-M.O., K.J.), Nuffield Department of Medicine (S.F.L., D.O., N.E.S., P.C.M., A.H., S.B.H., B.D.M., R.J.C., E.Y.J., D.I.S., G.S., D.E., S. Hoosdally, D.W.C., C.P.C., A.S.W., T.E.A.P., T.M.W.), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (N.E.S., P.C.M., S. Hoosdally, D.W.C., A.S.W., T.E.A.P., D.W.E.), the Kennedy Institute of Rheumatology Research (B.D...
Corresponding author: Eyre, David W.
ORCID: Lumley, Sheila F.
Stoesser, Nicole E.
Matthews, Philippa C.
Hatch, Stephanie B.
Marsden, Brian D.
Peck, Liam J.
Ritter, Thomas G.
Cornall, Richard J.
Stuart, David I.
Screaton, Gavin
Ebner, Daniel
Hoosdally, Sarah
Chand, Meera
Crook, Derrick W.
Conlon, Christopher P.
Pouwels, Koen B.
Walker, A. Sarah
Peto, Tim E.A.
Hopkins, Susan
Jeffery, Katie
Eyre, David W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-02-11
Volume: 384
Issue: 6
Pages: 533-540
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2034545
PMC: PMC7781098
OpenAlex: W3117382778
Cited by: 940
References: 29
Citations by year: 2026: 7 · 2025: 26 · 2024: 53 · 2023: 103 · 2022: 299 · 2021: 434
FWCI: 28.01
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: U.K. Government
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, COVID-19 reinfection, healthcare workers, anti-spike IgG, seropositivity, seroconversion, asymptomatic infection, symptomatic infection, infection incidence, antibody status
MeSH terms: Seroconversion, COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, United Kingdom, Health Personnel, Humans, Immunoglobulin G, Longitudinal Studies, Male, Middle Aged, Recurrence, Incidence, Polymerase Chain Reaction, Young Adult, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks